• Red Light Holland plans to rebrand as Rhelion Life Sciences, pending Canadian Securities Exchange clearance.
• Shift positions the group as a science-led psychedelic drug discovery and development platform following its Filament Health acquisition.
• Strategy centers on Filament’s patented, naturally derived psilocybin candidate PEX010, supported by expanded manufacturing, regulatory, and clinical research capabilities.
• Rebrand follows sector consolidation, citing Eli Lilly’s deal to buy AtaiBeckley for up to USD 3.8 billion as a recent signal.
• Trading symbols or an effective date were not disclosed; a follow-up release is expected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Red Light Holland Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607170750NEWSFILECNPR____20260717_305538_1) on July 17, 2026, and is solely responsible for the information contained therein.